UroGen Pharma (URGN) Revenue (2017 - 2026)

UroGen Pharma's Revenue history runs 10 years deep, the most recent figure standing at $51.0 million for Q1 2026.

• Quarterly Revenue rose 151.6% year-over-year to $51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.5 million (up 52.92% YoY) and the FY2025 annual result came in at $109.8 million, up 21.45% from the prior year.
• Revenue was $51.0 million for Q1 2026 at UroGen Pharma, up from $37.8 million in the prior quarter.
• Across five years, Revenue topped out at $51.0 million in Q1 2026 and bottomed at $13.6 million in Q1 2022.
• A 5-year average of $23.4 million and a median of $21.1 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue climbed 3.35% — and 2026, when it jumped 151.6%.
• UroGen Pharma's Revenue stood at $18.1 million in 2022, then soared by 30.06% to $23.5 million in 2023, then climbed by 4.4% to $24.6 million in 2024, then surged by 54.03% to $37.8 million in 2025, then jumped by 34.68% to $51.0 million in 2026.
• Business Quant data shows URGN's Revenue at $51.0 million in Q1 2026, $37.8 million in Q4 2025, and $27.5 million in Q3 2025.